Endometrial Cancer Clinical Trial
Official title:
Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)
This randomized, controlled study evaluates the efficacy of weigh loss interventions in endometrial cancer survivors, using novel technology-based weight loss platforms. This is a multi-site, pilot feasibility study which will provide preliminary data to support a larger NIH funded, mult-center trial.
Study Aims The relationship between endometrial cancer (EC) and obesity is well established.
However, few studies have examined the acceptability and potential efficacy of an
intervention to promote weight reduction and alter cancer-associated biomarkers in
endometrial cancer survivors. This investigation has two specific aims.
Aim 1:
To compare the efficacy of novel technology-based weight loss interventions: a) telephone
encounters and wireless scales, or b) smart phone personalized text messaging as compared to
c) an enhanced usual care group for women with obesity and a history of endometrial cancer.
Hypothesis: Women in both the telemedicine and text intervention arms will lose
significantly more weight than women in the enhanced usual care arm.
Aim 2:
1a) To explore patients' understanding of the relationship between obesity and endometrial
cancer and, 1b) to survey the acceptability of novel and different approaches to weight
loss.
Hypothesis: The investigators anticipate that this study will validate pilot data from a
predecessor single-institution study demonstrating that >25% of patients will not be aware
of the association between excess body weight and endometrial cancer. Investigators also
will assess the acceptability of various interventions designed to promote weight loss (i.e.
in person counseling, phone-based, text messaging) and predict a greater interest in
interventions that require fewer in-person visits to the clinic.
Study Design
Aim 1:
- 3 arm randomized controlled trial, weight loss intervention
- Pre and post intervention patient reported psychosocial measures
- Pre and post intervention Dual-energy X-ray absorptiometry (DEXA) to explore impact of
weight loss on body fat distribution
- Pre and post intervention analyses of the following biomarkers: insulin-like growth
factor-binding protein 1 (IGFBP-1); adiponectin, vascular endothelial growth factor
(VEGF), C reactive protein (CRP), interleukin 1-beta (IL1-beta), interleukin 2 (IL2),
interleukin 6 (IL6), interleukin 7 (IL7), and interleukin 8 (IL8)
Aim 2: Patient-reported survey to assess knowledge of correlation of Body Mass Index (BMI)
with endometrial cancer incidence
Study Population
Aim 2: Adult women with biopsy-proven endometrial cancer (Types I and II), BMI ≥ 30 kg/m2.
Aim 1: Aim 2 population plus Eastern Cooperative Oncology Group (ECOG) Performance Status
(PS) 0-1, no concurrent chemo or radiation therapy, and access to wireless internet and/or
smart phone device.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05796518 -
Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors
|
N/A | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06463028 -
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT03820024 -
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
|
N/A | |
Active, not recruiting |
NCT05082025 -
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
|
Phase 2 | |
Active, not recruiting |
NCT00587886 -
Estrogen, Diet, Genetics and Endometrial Cancer
|
||
Completed |
NCT05378152 -
Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity
|
N/A | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Recruiting |
NCT04569773 -
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Not yet recruiting |
NCT06073184 -
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
|
Phase 2 | |
Not yet recruiting |
NCT06366347 -
ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
|
Phase 2 | |
Not yet recruiting |
NCT05998798 -
Revealing Engagement Patterns Among Endometrial Cancer Patients
|
||
Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
Completed |
NCT02549989 -
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
|
Phase 2 |